论文部分内容阅读
目的探讨转移因子口服溶液治疗小儿哮喘的临床疗效。方法选择2010年1月-2012年1月于我院就诊的60例4到12岁的哮喘婴幼儿,应用随机数目表法将来院就诊的患儿分为治疗组32例(应用转移因子口服溶液组)和对照组28例。观察治疗前后酶联免疫吸附试验检测血清IgE、白细胞介素-4(IL-4)、γ-干扰素(IFN-γ)、白细胞介素-12(IL-12)、哮喘的发作程度的变化及疗效的评价。结果与对照组比较,治疗组患儿IL-4、IL-12、IFN-γ的变化有统计学意义(P<0.05),哮喘发作程度、临床疗效差异也存在显著差异(P<0.01)。结论转移因子口服溶液有明显治疗作用,可作为防治小儿哮喘的辅助治疗方法之一。
Objective To investigate the clinical efficacy of transfer factor oral solution in the treatment of pediatric asthma. Methods From January 2010 to January 2012, 60 infants and young children aged 4 to 12 years who were treated in our hospital were divided into treatment group (n = 32) by random number table method (application of transfer factor oral solution Group) and control group of 28 cases. Changes of serum IgE, IL-4, IFN-γ, IL-12 and asthma were measured before and after treatment by enzyme-linked immunosorbent assay And the evaluation of curative effect. Results Compared with the control group, the changes of IL-4, IL-12 and IFN-γ in the treatment group were statistically significant (P <0.05). There were also significant differences in the degree of asthma attack and clinical efficacy (P <0.01). Conclusion The transfer factor oral solution has a significant therapeutic effect and can be used as adjuvant therapy in the prevention and treatment of pediatric asthma.